According to Yongan Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock exceeded 20% for 2 consecutive trading days on July 15 and 16, 2026, which is an abnormal fluctuation. After verification, there was no need to correct or supplement the information disclosed by the company in the early stages. No major information was disclosed in media reports, the business situation and internal and external environment were normal, the company, controlling shareholders, and actual controllers did not trade the company's shares during the period of abnormal fluctuations. The company reminds investors to invest rationally and pay attention to risks.

According to Yongan Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock exceeded 20% for 2 consecutive trading days on July 15 and 16, 2026, which is an abnormal fluctuation. After verification, there was no need to correct or supplement the information disclosed by the company in the early stages. No major information was disclosed in media reports, the business situation and internal and external environment were normal, the company, controlling shareholders, and actual controllers did not trade the company's shares during the period of abnormal fluctuations. The company reminds investors to invest rationally and pay attention to risks.